A proposal for the rational use of the PET in oncology;Una propuesta para el uso racional de la PET en oncología

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 3, 2002, Pages 163-173

  Borrego Dorado, I ^a   Vazquez Albertino R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Clinical practice guide; Oncological indications; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE; RADIOACTIVE IODINE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN TUMOR; CANCER RECURRENCE; CANCER RISK; CANCER SCINTISCANNING; CANCER STAGING; CLINICAL PROTOCOL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; COST EFFECTIVENESS ANALYSIS; DIFFERENTIAL DIAGNOSIS; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; METASTASIS; NUCLEAR MEDICINE; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SPAIN; THYROID CANCER; THYROID MEDULLARY CARCINOMA; COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; ECONOMICS; HEAD AND NECK TUMOR; LUNG COIN LESION; LUNG TUMOR; NEOPLASM; PRACTICE GUIDELINE; REVIEW; SCINTISCANNING;

BRAIN NEOPLASMS; COIN LESION, PULMONARY; COLORECTAL NEOPLASMS; CONSENSUS; COST-BENEFIT ANALYSIS; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; LYMPHOMA; MELANOMA; NEOPLASMS; PRACTICE GUIDELINES; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; SPAIN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036582131     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(02)72056-9     Document Type: Article

References (30)

1. Baum RP, Presselt N, Bonnet R. Pulmonary Nodules and Non-Small-Cell Bronquial Carcinoma. En: Ruhlmann J, Oehr P, Biersack H.-J, eds. PET in Oncology. Basics and Clinical Applications. New York: Springer; 1999. p. 102-19.
2. 18fluorine fluorodeoxyglucose positron emission tomography correlation. Diagn Cytopathol. 2000;22(2):92-6.
3. Michael K Gould, Glen A Lillington. Strategy and cost in investigating solitary pulmonary nodules. Chest 1997;112:418-22.
4. García Pérez M, Rodríguez Sánchez A. Cáncer de Pulmón. En: Cruz Hernández J.J. eds. Oncología Clínica. Madrid: Aran; 1999. p. 213-27.
5. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastasis from non-small cell lung cancer: mediastinal staging in the 1990 s-meta-analytic comparison of PET and CT. Radiology 1999;213(2):530-6.
6. Remge M, Pieterman MD, John WG, Van Putten, MD, Jacobus J, Meuzelaar MD. Preoperative staging of non-small-cell lung cancer with positron emission tomography. N Engl J Med 2000:343:254-61.
7. Coleman RE. PET in lung cancer. J Nucl Med 1999;40(5):814-20.
8. José Ángel Richter, W. Torre, Cristina Gámez, José Manuel Aramendia, Aurora Crespo, Anabel Nicolás, et al. Valor de la tomografía por emisión de positrones (PET)-18FDG en el cáncer de pulmón. Med Clin (Barc); 113:567-71.
9. Cohen A, Minsky B, Schilsky R. Cancer of the colon. En: De Vita VT, Hellman S, Rosemberg SA. Cancer: principles and Practice of Oncology. 5th ed. Lippincott. Philadelphia. 1997;1114-1184.
10. Huebner RH, Park KC, Shepherd JE, Schwimmer J, Czernin J, Ph... Gambhir SS. A meta-analysis of he literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000;41(7):1177-89.
11. 18]fluorodeoxy glucose in manegement of recurrent Colorectal cancer. Arch Surg 1999;134(5):503-13.
12. Valk PE, Poinds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveneses of PET imaging in clinical oncology. Nuclear Med Biol 1996;23:737-43.
13. 18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch-Surg. 1999;134(5):503-11; discussion 511-3.
14. th Edition. De Vita VT, Hellman S, Rosemberg SA, eds. J.B. Philadelphia: Lippincott; 1997. p. 1947-94.
15. Schwimmer J, Essner R, Patel A, Jaham SA, Shepherd JE, Park-K, et al. A review of the literature for whole-body FDG PET in the manegement of patients with melanoma. Q J Nucl Med 2000;44(2):153-67.
16. Michael M, Maisey R, Richard L, Wahl Sally F, Barrington. Lymphoma. En: Michael M. Maisey. R. Richard L. Wahl. Sally F. Barrington eds, Atlas of Clinical Positron Emission Tomography. Great Britain: Arnold; 1999. p. 51-74.
17. Partrige S, Timothy A, O'Doherty MJ, Hain SF, Rankin S & Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. Annals of Oncology. 2000;11:1273-9.
18. Stumpe KD, Urbinelli M, Steinert HC, Glanzman C, Buck A, Von Schulthess GK. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25(7):721-8.
19. Shaah N, Hoskin P, Macmillan A, Gibson P, Lowe J, Wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. The Britsh Journal of Radiology 2000;73:482-7.
20. Michael M, Maisey, Richard L, Wahl, Sally F. Barrington. Head and neck cancer. En: Michael M. Maisey, Richard L. Wahl, Sally F. Barrington, eds. Atlas of Positron Emission Tomography. New York: Arnold; 1999. p. 129-49.
21. Laubenbacher C, Kau RJ, Alexiou C, Arnold W, Schawaiger M. Head and Neck Tumors. In: Ruhlmann J, Oehr P, Biersack HJ. eds. PET in Oncology. Basics and Clinical Applications. Berlin: Springer; 1999. p. 76-87.
22. 18F- fluorodeoxyglucose in detecting residual/recurrent squamons cell carcinoma of the head and neck. Am J Neuroradiol. 1998;19(7):1189-96.
23. 18Fluorine fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26(12):1547-52.
24. 18fluorine fluorodeoxyglucose PET in patients with medullary thyroid cancer. Europ J Nucl Med 2000; 27(5):490-96.
25. Barker FG, Chang SM, Valk PE. and all. 18-Fluorodeoxyglucose uptake and survival patients with suspected recurrent malignant glioma. Cancer 1997;115-126.
26. Biersack HJ, Willkomm P, An R, Ruhlmann J. Brain Tumors. En: Ruhlmann J, Oehr P, Biersack H.J. eds. PET in Oncology. Basics and Clinical Applications. Berlin: Springer; 1999. p. 171-7.
27. Daniel D. Langleben, George M. Segall. PET in Differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-1867.
28. Stephen Skehan, Andrea L. Brown, Margo Thompson, Edward M, Geoffrey Coates, Claude Nahmias. Imaging features of primary and Recurrent esophageal cancer at FDG PET. RadioGraphics 2000:20:713-23.
29. 18fluorine-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Medicine 1998:39:431-5.
30. Karl H, Bohuslavizki, Susanne Klutmann, Sabine Kröger, Uwe Sonnemann. TOD The Journal of Nuclear Medicine 2000;51 (5):816-22.